
Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.
Chief Commercial Officer at ActivePure Technologies.

Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.

ActivePure’s Deborah Birx, MD, and Amy Carenza, BBA, discuss their study showing a 99% reduction in fungal colony-forming units, 98% reduction in aerobic bacteria, and a 66% decrease in C auris.

Published: November 6th 2024 | Updated:

Published: November 5th 2024 | Updated: